Revolution Medicines Surges on Regulatory Progress and Backing from Stanley Druckenmiller
Revolution Medicines (NASDAQ: RVMD) has surged 125% in 2026, driven by positive Phase 3 trial results for its experimental drug Daraxonrasib. The FDA granted Breakthrough Therapy and Orphan Drug designations to the treatment, which is nearing a New Drug Application submission. Additionally, billionaire Stanley Druckenmiller's Duquesne Family Office increased its stake in Revolution Medicines during Q1 2026.
Tickers: $RVMD
Topics: biotechnology clinical trials EMA FDA